Your trusted source for investing success

Tag: Patent

Nemaska Lithium Releases 2018 Feasibility Study

Nemaska Lithium Releases 2018 Feasibility Study

Nemaska Lithium Inc. (TSX:NMX)(OTCQX:NMKEF)(FRANKFURT:N0T) is pleased to announce the results of its 2018 Feasibility Study on the Whabouchi Mine and Concentrator located in the Eeyou Istchee James Bay territory in Québec, and on the Hydromet Plant located in Shawinigan, Québec.

Nemaska Lithium Delivers Second Shipment of Battery Grade Lithium Hydroxide from Whabouchi Concentrate and Releases Product Purity Specifications

Nemaska Lithium Delivers Second Shipment of Battery Grade Lithium Hydroxide from Whabouchi Concentrate and Releases Product Purity Specifications

Nemaska Lithium Inc. (TSX:NMX)(OTCQX:NMKEF)(FRANKFURT:N0T) is pleased to announce that it has produced and has made available for pick-up by its customer, another 2 tonnes of battery grade lithium hydroxide solution, made from Whabouchi spodumene concentrate. To date, the Corporation has delivered 3 tonnes of lithium hydroxide solution produced from its Whabouchi

2017 Wrap-Up by Lexaria’s CEO

2017 Wrap-Up by Lexaria’s CEO

Lexaria Bioscience Corp. (OTCQX:LXRP, CSE:LXX) (the “Company” or “Lexaria”) announces it’s been quite an amazing year for Lexaria stakeholders – the busiest and most productive we’ve had. I’ve welcomed so many new shareholders and Lexaria fans in 2017 and I want to ensure both our new followers as well as our

Lexaria Bioscience Files S4 Prospectus to Re-Domicile To Canada

Lexaria Bioscience Files S4 Prospectus to Re-Domicile To Canada

Lexaria Bioscience Corp. (OTCQX:LXRP,CSE:LXX) (the ”Company” or ”Lexaria”) announces that, on January 5, 2018, it filed a registration statement and shareholder information circular on Form S-4 with the US Securities and Exchange Commission (the ”SEC”) pursuant to which Lexaria will seek shareholder approval to change its corporate domicile from the

Revive Therapeutics Announces Update on its Collaboration Agreement with Health Canada Licensed Dealer for Medical Cannabis…

Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid-based pharmaceutical markets, today announced an update on the Company’s collaboration agreement with Chemi Pharmaceutical Inc. (“Chemi Pharma”), a Licensed Dealer for

How to Invest in Cleantech

How to Invest in Cleantech

The cleantech sector is one of the most important industries today, and investor interest on the rise. Here’s an overview of how to invest in cleantech.

Looking for Cannabis Stocks?


Read our report to find market data, important news and stocks to watch!


Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Luminor Medical to Acquire Rise Research Inc., Licensor of the Company's Cannabis Commercial Products

URL: https://investingnews.com/daily/life-science-investing/medical-device-investing/luminor-medical-acquire-rise-research-inc-licensor-companys-cannabis-commercial-products/